Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorzoxazone + diclofenac + paracetamol
- Development stage
- Unknown
- Lead developer
- Croise Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CROISE-MR is a fixed-dose combination tablet containing the muscle relaxant chlorzoxazone, the non-steroidal anti-inflammatory drug (NSAID) diclofenac (as diclofenac potassium), and the analgesic/antipyretic paracetamol (acetaminophen). Developed by Croise Pharma, it is indicated for the treatment of acute, painful musculoskeletal conditions, muscle spasms, and associated pain, inflammation, and tension. Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs, thereby reducing muscle spasm. Diclofenac inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) to reduce prostaglandin synthesis, alleviating pain and inflammation. Paracetamol acts primarily in the central nervous system to provide additional analgesic and antipyretic effects.
- Brand names
- Croise-MRCroise-MR Tablet
- Other names
- chlorzoxazone + diclofenac potassium + paracetamol
02
Targets
KCNMA1 (Calcium-activated potassium channel subfamily M alpha member 1)SPHK2 (Sphingosine kinase 2)KCNN4 (Intermediate conductance calcium-activated potassium channel protein 4)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on chlorzoxazone + diclofenac + paracetamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorzoxazone + diclofenac + paracetamol.